Compare Honeywell International Inc (HON) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Revvity Inc — how do they compare? Honeywell International Inc trades at $207.6 (market cap $65.48B), while Revvity Inc trades at $153.89 (market cap $16.98B). The key difference: Honeywell International Inc is far larger — about 3.9× Revvity Inc's market cap, and Honeywell International Inc pays the higher dividend (1.36%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Revvity Inc for 12 Days on average.
| HON | RVTY | |
|---|---|---|
Market Cap | $65.48B | $16.98B |
Volume | 2,047,782 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $248.79 | $157.36 |
52-Week Low | $188.14 | $82.26 |
Typical Hold Time | 90 Days | 12 Days |
Enterprise Value | $90.27B | $19.30B |
Dividend Yield | 1.36% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal from moving averages but strong fundamentals including a low P/E of 7.94 and robust ROE of 47.43%. Recent earnings beats and a $300 million refinery project win highlight operational strength, while the company's post-spin focus on automation drives growth expectations.
The outlook is positive with a consensus price target of $259.25 implying 24.6% upside, supported by analyst bullishness (66.7% buy ratings). Risks include rising debt-to-asset ratios and cyclical exposure, but solid cash flow and dividend payments provide stability amid near-term volatility.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
